Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 PFS and AI in primary hypercholesterolemia and mixed dyslipidemia
CTR20220027Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ongericimab in hypercholesterolemia, combined dyslipidaemia, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2022; status: completed.
02
Drugs
ongericimab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220027.